April 2012

Critical Access Hospitals Losing Lab Test Work

CEO SUMMARY: One consequence of a new “site of service” health plan instituted by Anthem Blue Cross and Blue Shield in New Hampshire is that community hospitals—particularly in rural areas—are being asked by patients to collect blood and lab specimens, then send them off to Anthem’s network laboratories. One New Hampshire hospital CEO explains how […]

To access this post, you must purchase The Dark Report.

Critical Access Hospitals Losing Lab Test Work Read More »

Ohio Lab Offers Lessons Learned from CAP 15189

Laboratory Management / Joseph Burns

CEO SUMMARY: For a lab looking to continually improve lab operations, becoming accredited to either ISO 15189 or CAP 15189 is an ideal challenge. After hearing from other lab directors about the benefits of becoming accredited to CAP 15189, the staff at Mercy Medical Center in Canton, Ohio, believed that accreditation to this standard would

To access this post, you must purchase The Dark Report.

Ohio Lab Offers Lessons Learned from CAP 15189 Read More »

LifeLabs, Gamma-Dynacare, Sonic Healthcare, Brigham & Women’s Hospital, Massachusetts General Hospital

Clinical Laboratory / Robert Michel

LIFELABS QUEBEC TO BE ACQUIRED BY GAMMA-DYNACARE LAST WEEK, IT WAS ANNOUNCED that Gamma-Dynacare Medical Laboratories had signed a definitive agreement with LifeLabs Limited Partnership to purchase LifeLabs Quebec. Both parties expect the transaction to close by April 28, 2012. This laboratory acquisition is notable for at least three reasons. First, it involves Canada’s two primary

To access this post, you must purchase The Dark Report.

LifeLabs, Gamma-Dynacare, Sonic Healthcare, Brigham & Women’s Hospital, Massachusetts General Hospital Read More »

Exome Sequencing Next “Big Thing” for Diagnosis

Genetic Testing / Joseph Burns

CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—the workhorse machinery of the cell—researchers identify dis- ease causes much faster than

To access this post, you must purchase The Dark Report.

Exome Sequencing Next “Big Thing” for Diagnosis Read More »

April 2, 2012 “Intelligence: Late Breaking Lab News”

Late Breaking Lab News / Robert Michel

Like a tenacious bulldog, Roche Holding AG continues its determined effort to acquire Illumina, Inc., the company that makes gene sequencing systems. Last week, Roche increased its offer from $44.50 per share to $51 per share for Illumina stock. That raises the price Roche says it will pay to $6.5 billion, which is 15% greater

To access this post, you must purchase The Dark Report.

April 2, 2012 “Intelligence: Late Breaking Lab News” Read More »